ANG Lifesciences India Ltd

ANG Lifesciences India Ltd has submitted its Annual Report for the Financial Year 2025-26, along with the notice for its 20th Annual General Meeting (AGM). The AGM is scheduled for September 30, 2026, and will be conducted via video conferencing. Key agenda items include the adoption of audited standalone and consolidated financial statements for FY26, the re-appointment of Mr. Rohit Mittal as a director retiring by rotation, ratification of Cost Auditor remuneration for FY27, and the re-appointment of Mrs. Chetna as an Independent Director. The company has also confirmed that the Annual Report has been uploaded to its website.

ANG Lifesciences India Ltd has announced its 20th Annual General Meeting (AGM) will be held on Wednesday, September 30, 2026, at 12:00 PM. The meeting will be conducted through Video Conferencing (VC)/ Other Audiovisual Means (OAVM) in compliance with circulars from the Ministry of Corporate Affairs and SEBI. Key agenda items include the adoption of audited standalone and consolidated financial statements for the fiscal year ended March 31, 2026, the re-appointment of Mr. Rohit Mittal as a director, ratification of cost auditor remuneration for FY 2026-27, and the re-appointment of Mrs. Chetna as an Independent Director for a second five-year term.

ANG Lifesciences India Ltd has announced that its 20th Annual General Meeting (AGM) will be held on Wednesday, September 30, 2026, at 12:00 PM. The meeting will be conducted through Video Conference (VC) or Other Audio Visual Means (OAVM), in compliance with relevant circulars from the Ministry of Corporate Affairs (MCA) and SEBI. This intimation serves as a formal notification to shareholders for their information and record.

ANG Lifesciences India Ltd's Board of Directors met on September 7, 2026, approving key corporate actions. The board appointed M/s Shreya Sahu & Associates as the Cost Auditor for FY 2026-27 and approved the Board's report for FY 2025-26. The 20th Annual General Meeting is scheduled for September 30, 2026, with a book closure period from September 24 to September 30, 2026. The board also approved the re-appointment of Mr. Rohit Mittal and Mrs. Chetna as an Independent Director for a second five-year term, subject to shareholder approval.

ANG Lifesciences India Ltd announced its standalone and consolidated un-audited financial results for the quarter ended June 30, 2026. The Board of Directors approved these results in a meeting held on August 14, 2026. A limited review report for the same period was also presented. The company operates in Pharmaceuticals and Printing & Packaging segments. Detailed financial figures for revenue, expenses, and profit/loss for both standalone and consolidated statements were provided, along with segment-wise performance.

ANG Lifesciences India Ltd has announced the submission of its standalone and consolidated unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved these results, along with the Limited Review Report, during a meeting held on August 14, 2026. The financial results were reviewed by the Audit Committee prior to board approval. The filing indicates that the results pertain to the first quarter of the fiscal year 2027.

ANG Lifesciences India Ltd has announced a Board of Directors meeting scheduled for August 14, 2026. The primary agenda is to consider and approve the standalone and consolidated un-audited financial results for the quarter ended June 30, 2026. The company has also informed that the trading window for its securities will remain closed from July 1, 2026, until 48 hours after the results are made public.

ANG Lifesciences India Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is effective from July 1, 2026, and will remain in effect until 48 hours after the declaration of the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. The company has advised all designated persons and their immediate relatives not to trade in its securities during this period, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The date of the board meeting to consider these financial results will be intimated separately.

ANG Lifesciences India Ltd. announced audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The Board of Directors approved these results on May 30, 2026, following a review by the Audit Committee. The company's revenue from operations for the year ended March 31, 2026, stood at ₹9,160.45 lakhs compared to ₹8,991.01 lakhs in the previous year. The company reported a profit after tax of ₹110.25 lakhs for the quarter ended March 31, 2026.

ANG Lifesciences India Ltd has announced its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. Key figures from the standalone results include revenue from operations of ₹9,160.45 lakhs for the year ended March 2026, compared to ₹8,991.01 lakhs in the previous year. The company reported a profit of ₹110.25 lakhs for the year, a significant decrease from the previous year's loss of ₹1,034.29 lakhs. The board meeting, where the results were approved, commenced at 5:00 PM and concluded at 09:50 PM on May 30, 2026.